Breast Gene Discovery Could Transform Treatment

Thursday, 07 Feb 2013 02:12 PM

By Nick Tate

  Comment  |
   Contact  |
  Print   |
    A   A  
  Copy Shortlink
Scientists have discovered a genetic defect implicated in the majority of breast cancers — a finding that may change the way the disease is diagnosed and treated.

In a new report in the journal Nature, University of Minnesota researchers said they have identified a human enzyme that causes DNA mutations seen in breast cancer patients. The identification of the enzyme — called APOBEC3B — could pave the way for the development of new screening tests, prevention approaches, and therapies for breast cancer.

"We strongly believe this discovery will change the way mutations in cancer are viewed,” said Reuben Harris, an associate professor of biochemistry, molecular biology, and biophysics who helped lead the research that led to the finding. “And, hopefully, it will allow cancer researchers to develop new treatments [and] approaches that can prevent these mutations before they become harmful."

Special: This Small Group of Doctors are Quietly Curing Cancer

The discovery by Harris and colleagues was an outgrowth of the team’s HIV research, which had found APOBEC3B and related enzymes can protect people from some infectious viruses. But in studying the enzyme, Harris and his team found DNA mutations cause APOBEC3B to be produced in great quantities in breast cancer patients’ cell lines and tumors.

As a result, the enzyme is a biological "double-edged sword" — offering protection from some viruses, such as HIV, but produces mutations that promote cancer, he said.

"DNA mutations are absolutely essential for cancer development," said Harris. "Our experiments showed the APOBEC3B enzyme causes mutations in the genome of breast cancer cells. From this, we were able to reasonably conclude that the APOBEC3B is a key influencer in breast cancer."

Harris said the findings suggest high APOBEC3B levels could be tracked to indicate the early presence of breast cancer through a simple blood test that could speed treatments.

The research may also pave the way for developing new drugs that block APOBEC3B from causing DNA mutations, “just as sunscreen prevents sun from causing mutations leading to melanoma,” he said.

“Ultimately, we hope our discovery leads to better therapeutic outcomes for patients," added Harris.

© 2014 NewsmaxHealth. All rights reserved.

  Comment  |
   Contact  |
  Print   |
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

New Ovarian Cancer Drug Gets FDA OK

Friday, 19 Dec 2014 15:48 PM

The U.S. Food and Drug Administration has approved a new drug to treat advanced ovarian cancer, along with a test to ide . . .

'Surveillance' Best Approach for Low-Risk Prostate Cancer: Study

Friday, 19 Dec 2014 12:39 PM

Among men whose low-risk prostate cancer was managed with so-called active surveillance for up to 15 years, just 1.5 per . . .

E-Cigs Less Addictive Than Regular Cigarettes, Say Researchers

Friday, 19 Dec 2014 12:35 PM

Former tobacco smokers find e-cigarettes less addictive than traditional cigarettes, new research finds. Even though the . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved